24 news items
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
APLS
10 Jun 24
)SYFOVRE® (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy (GA). By targeting
Piper Sandler Initiates Coverage On Apellis Pharmaceuticals with Neutral Rating, Announces Price Target of $46
APLS
31 May 24
Piper Sandler analyst Biren Amin initiates coverage on Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral rating and announces Price Target of $46.
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
APLS
28 May 24
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing
HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
APLS
28 May 24
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 price target.
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
APLS
24 May 24
investigating systemic pegcetacoplan, a targeted C3 therapy, for the treatment of post-transplant recurrence of C3 glomerulopathy (C3G) and primary immune
fz5ol uzv
APLS
23 May 24
Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Equal-Weight and lowers the price target from $57 to $48.
1wr8acktd9cx3ydov
APLS
8 May 24
Citigroup analyst Yigal Nochomovitz maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $67 to $60.
mw797v7mpb01j9sn6uulpx658e7xmhelh01scrp5c8ui4
APLS
8 May 24
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 price target.
lo67ijwaot2al6 0dtjass
APLS
8 May 24
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $77.14
1kdos9w1igsf9nc9l3r4cmz0s8ccbpda6gxjk2spxfgpz74my8cgrrlw
APLS
8 May 24
UBS analyst Eliana Merle maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $89 to $85.
jhf4oo47dkxz7vs dr8xhfvrebe1aewm1b4fb9qdgxudgwpo44nw3f8ule0x
APLS
8 May 24
Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.
yvjogcqvm5kp4dnrxicpgv0ds728m2bwmuxva62p0m7fz7un
APLS
7 May 24
)SYFOVRE® (pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE
b2jwnm4tjo lhd25kkvs
APLS
6 May 24
and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around
o4a8ln8lfvb82oekgs32iod9shkd53827g6 rvz96q1f
APLS
1 May 24
(pegcetacoplan injection) is the first-ever approved therapy for geographic atrophy (GA). By targeting C3, SYFOVRE is designed to provide comprehensive control
dyhtxu
APLS
26 Apr 24
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 price target.
gepn lc94nw6wyw4vwwebn3nlg
APLS
26 Apr 24
of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading
rvyq9q517bhyvjtdo6hzfz6xa2t5bcq 6n21p2g
APLS
25 Apr 24
Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $85 price target.
nilyh8yg9bdpfcn6nb8acs919qt71
APLS
17 Apr 24
Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target from $67 to $57.
geyzeiubfw s2zf
APLS
15 Apr 24
0
The 12-month price targets, analyzed by analysts, offer insights with an average target
894 f6gnzyc065ox12eenr1pqhlab1hj0umsclb6lkducmwymi67rix
APLS
15 Apr 24
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $92 price target.